Actively Recruiting

Phase Not Applicable
Age: 18Years - 85Years
All Genders
NCT05679427

Ablative Radiosurgery vs Stereotactic RT in 5 Fractions With SIB for Oligometastatic Bone Lesions

Led by IRCCS San Raffaele · Updated on 2025-06-11

307

Participants Needed

1

Research Sites

265 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a randomised prospective monoinstitutional study comparing radiosurgery at a total dose up to 24 Gy to five fraction stereotactic radiotherapy with simultaneous integrated boost (SIB) up to 50 Gy for the treatment of bone metastases in oligometastatic cancer treated with radical intent. At the end of the first 12 months from the start of the study an interim analysis will be performed taking into account all major endpoints for an initial evaluation of the study , with only an observational purpose, without subsequent protocol changes.

CONDITIONS

Official Title

Ablative Radiosurgery vs Stereotactic RT in 5 Fractions With SIB for Oligometastatic Bone Lesions

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Performance status ECOG 642
  • Life expectancy greater than 6 months according to Mizumoto criteria
  • Oligometastatic disease with 1 to 5 metastases, including synchronous or metachronous involvement of up to three organs (lymph nodes, bones, lungs, liver, adrenal gland, brain) with known histology
  • At least one bone metastasis suitable for stereotactic ablative radiotherapy or radiosurgery
  • Each metastatic site must be treated with curative intent
  • Patients may have received prior anticancer treatments including surgery, chemotherapy, or radiotherapy for other metastatic sites
Not Eligible

You will not qualify if you...

  • Disease sites not suitable for stereotactic radiotherapy
  • Serious medical conditions that prevent radiotherapy
  • Overlapping area with previously treated radiotherapy volume
  • Lesion size greater than 5 cm for extracranial sites
  • Lesion size greater than 3 cm for brain metastases
  • More than one brain metastasis
  • Clinical or imaging evidence of spinal cord compression or tumor within 2 mm of spinal cord
  • Imaging evidence of vertebral body fracture or involvement of more than 40% of vertebral body
  • Imaging evidence of cortical involvement in long bones
  • Pregnant or breastfeeding women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

San Raffaele Scientific Institute

Milan, MI, Italy, 20132

Actively Recruiting

Loading map...

Research Team

N

Nadia G Di Muzio, Prof.

CONTACT

A

Andrei Fodor, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here